Bias found in mental health drug research presented at major psychiatric meeting

May 22, 2012, University of Michigan Health System

When thousands of psychiatrists attend their field's largest annual meeting each year, the presentations they hear about research into drug treatments report overwhelmingly on positive results.

That's the finding of a new study published in the Journal of Clinical Psychopharmacology by two young psychiatrists from the University of Michigan and Yale University, who analyzed the presentations given at two recent meetings of the .

Of 278 studies presented at the 2009 and 2010 APA meetings that compared at least two medicines against each other for any , they found that 195 had been supported by industry, and 83 funded by other means. The authors then evaluated the studies without knowing which kind of support each one had.

Of the industry-supported studies, 97.4 percent reported results that were positive toward the medicine that the study was designed to test, and 2.6 percent reported mixed results. No industry-sponsored studies with negative results were found.

In contrast, when industry was not the source of funding, 68.7 percent of the presentations were positive, and 24.1 percent contained mixed results, while 7.2 percent contained negative results.

This 'presentation bias', in which mostly good news about medicines gets reported at meetings, the 'publication bias' that has been seen in research published in major journals, says Srijan Sen, M.D., Ph.D., an assistant professor of psychiatry at the U-M Medical School who led the study while in his residency at Yale.

While attending the APA's massive annual meeting, he noted the large industry presence and emphasis on research involving medicines that were still "on patent" and being actively marketed to both psychiatrists attending the conference. He teamed with Yale psychiatry resident Maya Prabhu, M.D., M.Sc., now a consulting forensic psychiatrist at Yale, to do a formal review.

"This analysis suggests that the APA meeting might be being used as an opportunity to make drugs seem more effective than they are," he says.

Meanwhile, research on "talk therapy" treatments such as cognitive behavioral therapy – which doesn't have industry backing – gets less attention, even though there is growing evidence that such non-drug therapies can have as much effect as medicines in illnesses such as depression.

Since the APA meeting is a major source of continuing medical education credit for psychiatrists, and a hub for psychiatry residents just starting out in the field, the bias has the potential to affect their clinical care when they return home.

Sen notes that the research journals and funding agencies have tried to confront research bias in journal articles by requiring pharmaceutical companies to register the clinical trials they are conducting and include the registration number when publishing the study. This allows interested individuals to see which trials are being reported in the medical literature, and whether the trial results are interpreted according to the original study design.

For instance, if a drug trial is designed to test long-term results from a particular treatment, but a paper is published showing positive over a much shorter term, that could be an indication of bias. Research meetings could require a similar practice, Sen says. And, APA could be more selective in accepting poster presentation submissions.

If nothing else, Sen says, attendees at the APA's meeting – and perhaps other large gatherings of psychiatrists – should be aware of the positive bias of the research they will hear about at the meeting.

And, non-industry funding for research – especially research to compare older "off patent" drugs that aren't being marketed by industry – is also important, he says. The federal government has funded large comparison studies in depression, schizophrenia and bipolar disorder, he notes – and these mostly showed that the generic medications that have lost their patent protection are just as effective as newer, patent-protected ones. But even still, prescribe the generic ones far less often than the brand-name patent-protected ones.

Explore further: Publication bias involving psychiatric medications may provide physicians with an incomplete picture

More information: Journal of Clinical Psychopharmacology, Volume 32, Number 3, June 2012.

Related Stories

Publication bias involving psychiatric medications may provide physicians with an incomplete picture

March 20, 2012
Physicians who prescribe antipsychotic medications may be basing their decisions on incomplete information, according to new research published by scientists at Oregon Health & Science University. The study is published in ...

Recommended for you

Study: No evidence to support link between violent video games and behaviour

January 16, 2018
Researchers at the University of York have found no evidence to support the theory that video games make players more violent.

Study listens in on speech development in early childhood

January 15, 2018
If you've ever listened in on two toddlers at play, you might have wondered how much of their babbling might get lost in translation. A new study from the University of Toronto provides surprising insights into how much children ...

Study suggests people dislike you more for humblebragging than for regular boasting

January 12, 2018
A team of researchers from Harvard University and UNC-Chapel Hill has conducted a study regarding humblebragging—in which a person boasts about an achievement but tries to make it sound less boastful by minimizing it—and ...

Study identifies brain circuit controlling social behavior

January 11, 2018
A new study by researchers at Roche in Basel, Switzerland has identified a key brain region of the neural circuit that controls social behavior. Increasing the activity of this region, called the habenula, led to social problems ...

Can writing your 'to-do's' help you to doze? Study suggests jotting down tasks can speed the trip to dreamland

January 11, 2018
Writing a "to-do" list at bedtime may aid in falling asleep, according to a Baylor University study. Research compared sleep patterns of participants who took five minutes to write down upcoming duties versus participants ...

Tamper-resistant oxycodone tablets have no impact on overall opioid use

January 11, 2018
The introduction of tamper-resistant opioid tablets does not have an effect on rates of opioid use or harms at a population level, according to a new study led by the National Drug and Alcohol Research Centre (NDARC) at UNSW ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.